0:03
Hello everyone. I'm Ahik. I'm a rheumatologist based in São Paulo, Brazil.
0:08
And now I'm here to talk about T cell engagers in rheumatology.
0:14
I'm going to talk about two points. First point, how long does the effect last?
0:21
And the second point, what is the price in infection?
0:24
First, the idea — what is the T cell engager?
0:35
The T cell engager is an antibody with two arms.
0:36
One arm holds a T cell, the other one holds a B cell.
0:37
The T cell then kills the B cell, and it works like CAR-T, but there is no cell production and no manufacturing.
0:42
Abstract 2161 followed 21 patients up to 2 years.
0:49
These patients have received different engagers involving CD19, CD20, or BCMA.
0:59
This control lasts up to 2 years, but most patients had infections.
1:04
BCMA carries the high risk of infection especially because it removes also plasma cells.
1:12
So every patient that uses BCMA engagers needs to receive IVIG.
1:17
What's my read? My read is that the effect can last, but the price is infection, and it grows as much as the depth of the depletion.
1:29
So the targets really matter. BCMA brings the major problem for infection.
1:35
We still need longer follow-up and more randomized trials.
1:38
But that's it — the most important points to bring about infection and what T cell engagers can help in rheumatology.
1:50
Thank you. I'm Ahik. Keep tuning in to RheumNow.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.